InterVentional Technologies
This article was originally published in The Gray Sheet
Executive Summary
Plans to begin a randomized trial in April of its Barath surgical balloon dilatation catheter at ten sites in the U.S., IVT Chairman and CEO Robert Reiss reported Feb. 3 at the fifth annual Piper Jaffray cardiovascular conference in New York City. The device also will be studied in a six-country, non-randomized Phase II trial slated to begin March 1. Phase I trials of 17 patients in the U.S. and 17 patients in Europe have been completed ("The Gray Sheet" Dec. 7, In Brief), and six month followup on ten patients has shown a 0% restenosis rate, Reiss said. IVT hopes to introduce the device in Europe in January 1994.
You may also be interested in...
Vanda Comes Up Empty Handed As US Supreme Court Denies Hetlioz Appeal
Vanda looks likely to have to face up to unimpeded US generic competition to its core Hetlioz brand, after a further denial in its litigation against ANDA sponsors Teva and Apotex.
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.